Please ensure Javascript is enabled for purposes of website accessibility

Why Intra-Cellular Therapies Stock Is Skyrocketing Today

By Keith Speights – Sep 9, 2020 at 12:19PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors are reacting enthusiastically to the company's latest clinical results.

What happened

Shares of Intra-Cellular Therapies (ITCI -0.65%) were skyrocketing 80.3% higher as of 11:41 a.m. EDT on Wednesday. The huge jump came after the company announced positive results from a late-stage study evaluating lumateperone as adjunctive therapy to lithium or valproate in treating major depressive episodes associated with bipolar I or bipolar II disorder.

So what

Intra-Cellular Therapies has already picked up an FDA approval for lumateperone in treating schizophrenia. Its latest clinical results could mean that a second approved indication is on the way.

Document explaining bipolar disorder with eyeglasses on top of it

Image source: Getty Images.

The company reported that a once-daily 42 mg dose of lumateperone met both primary and key secondary endpoints of the late-stage study. The drug achieved statistically significant improvement in depression as measured by a change from the baseline versus placebo on the Montgomery-Asberg Depression Rating Scale (MADRS) and on the Clinical Global Impression-Bipolar Scale (CGI-BP-S).

Lumateperone also appeared to be generally well tolerated. Intra-Cellular Therapies stated that the most commonly reported adverse events included sleepiness, dizziness, and nausea.

Now what

Intra-Cellular Therapies now plans to file for FDA approval of lumateperone as adjunctive therapy in treating bipolar depression. There's also another potential catalyst for the biotech stock not too far into the future: Intra-Cellular plans to report results from a phase 3 study of lumateperone as a monotherapy in treating bipolar depression in the second half of 2021. 

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Intra-Cellular Therapies Stock Quote
Intra-Cellular Therapies
$47.15 (-0.65%) $0.31

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.